What are the economic and policy implications of PCSK9 inhibitors?
The economic and policy implications of PCSK9 inhibitors have been explored in several studies, including those by Bohula et al. (2017), Cannon et al. (2015), Giugliano et al. (2017), Sabatine et al. (2017), Schwartz et al. (2018) and Hlatky and Kazi (2017). These studies concluded that PCSK9 inhibitors can reduce the risk of cardiovascular events and are cost-effective in treating patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. Additionally, Kazi et al. (2016) found that the cost-effectiveness of PCSK9 inhibitor therapy in these patients is higher than that of statin therapy alone. Finally, Gandra et al. (2016) concluded that LDL-C lowering with evolocumab is cost-effective in patients with high cardiovascular risk in the United States.  